Choi, SU Kim, KH Choi, EJ Park, SH Kim, KM Shon, YS Lee, CO 2024-01-21T15:39:50Z 2024-01-21T15:39:50Z 2022-01-10 1999-04 0253-6269 https://pubs.kist.re.kr/handle/201004/142298 Despite the impressive antitumor activity of cisplatin, two major limitations of the drug, that is severe side effects and drug-resistance of cancer cells, make its use difficult for cancer therapy. These limitations have resulted in a great deal of effort having been expended into structural modifications of cisplatin. In this study, we tested two novel cisplatin analogues, (CPA)(2)Pt [DOLYM] (COMP-I) and (DACH)Pt[DOLYM] (COMP-II), for the mode of cytotoxic action against human tumor cells comparing with cisplatin and carboplatin in vitro. These two novel analogues had considerable cytotoxic activities against five kinds of human solid tumor cells, and especially COMP-II was more effective on HCT15 colon cancer cells than other compounds. In addition, COMP-II had cytostatic activity at low concentrations (10 similar to 0.3 mu g/ml), but other compounds revealed little effect on tumor growth at the tow concentration. English PHARMACEUTICAL SOC KOREA PERSPECTIVES CHEMOTHERAPY COMPLEXES Cytotoxicity of two novel cisplatin analogues, (CPA)(2)Pt[DOLYM] and (DACH)Pt[DOLYM], to human cancer cells in vitro Article 10.1007/BF02976539 1 ARCHIVES OF PHARMACAL RESEARCH, v.22, no.2, pp.151 - 156 ARCHIVES OF PHARMACAL RESEARCH 22 2 151 156 scie scopus 000079751000009 2-s2.0-0033110776 Chemistry, Medicinal Pharmacology & Pharmacy Pharmacology & Pharmacy Article PERSPECTIVES CHEMOTHERAPY COMPLEXES cisplatin cytotoxicity human cancer cells